BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11010234)

  • 21. Preferences for health outcomes and cost-utility analysis.
    Torrance GW
    Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?
    Jit M; Hutubessy R
    Appl Health Econ Health Policy; 2016 Jun; 14(3):245-52. PubMed ID: 26832145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Capabilities as menus: a non-welfarist basis for QALY evaluation.
    Bleichrodt H; Quiggin J
    J Health Econ; 2013 Jan; 32(1):128-37. PubMed ID: 23202258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluations and randomized trials in spinal disorders: principles and methods.
    Korthals-de Bos I; van Tulder M; van Dieten H; Bouter L
    Spine (Phila Pa 1976); 2004 Feb; 29(4):442-8. PubMed ID: 15094541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health utility indices and equity considerations.
    Bleichrodt H
    J Health Econ; 1997 Feb; 16(1):65-91. PubMed ID: 10167345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the welfare theoretic foundation of CEA: comment.
    Breyer F
    Eur J Health Econ; 2010 Dec; 11(6):595-6; discussion 597-8. PubMed ID: 20949303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of classic utilities to published pediatric cost-utility studies.
    Finnell SM; Carroll AE; Downs SM
    Acad Pediatr; 2012; 12(3):219-28. PubMed ID: 22075466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The importance of patient preferences for comorbidities in cost-effectiveness analyses.
    Harris RA; Nease RF
    J Health Econ; 1997 Feb; 16(1):113-9. PubMed ID: 10167342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of life and health economics: where is the link?
    Jönsson B
    Scand J Gastroenterol Suppl; 1996; 221():33-6. PubMed ID: 9110396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Costing and perspective in published cost-effectiveness analysis.
    Neumann PJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S28-32. PubMed ID: 19536023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the possibility of a bridge between CBA and CEA: comments on a paper by Dolan and Edlin.
    Hansen BO; Hougaard JL; Keiding H; Østerdal LP
    J Health Econ; 2004 Sep; 23(5):887-98. PubMed ID: 15353184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations of the Panel on Cost-effectiveness in Health and Medicine.
    Weinstein MC; Siegel JE; Gold MR; Kamlet MS; Russell LB
    JAMA; 1996 Oct; 276(15):1253-8. PubMed ID: 8849754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-social welfare functions: a reply to Hansen et al.
    Edlin R
    J Health Econ; 2004 Sep; 23(5):899-905. PubMed ID: 15353185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving value measurement in cost-effectiveness analysis.
    Ubel PA; Nord E; Gold M; Menzel P; Prades JL; Richardson J
    Med Care; 2000 Sep; 38(9):892-901. PubMed ID: 10982111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Bayesian approach to stochastic cost-effectiveness analysis.
    Briggs AH
    Health Econ; 1999 May; 8(3):257-61. PubMed ID: 10348420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Universal access to HIV treatment in developing countries: going beyond the misinterpretations of the 'cost-effectiveness' algorithm.
    Moatti JP; Marlink R; Luchini S; Kazatchkine M
    AIDS; 2008 Jul; 22 Suppl 1():S59-66. PubMed ID: 18664955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].
    Lakdawalla DN; Doshi JA; Garrison LP; Phelps CE; Basu A; Danzon PM
    Value Health; 2018 Feb; 21(2):131-139. PubMed ID: 29477390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should "standard gamble" and "'time trade off" utility measurement be used more in mental health research?
    Flood C
    J Ment Health Policy Econ; 2010 Jun; 13(2):65-72. PubMed ID: 20919593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Willingness to pay for a QALY: theoretical and methodological issues.
    Gyrd-Hansen D
    Pharmacoeconomics; 2005; 23(5):423-32. PubMed ID: 15896094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is the value of treating schizophrenia?
    Carr VJ; Lewin TJ; Neil AL
    Aust N Z J Psychiatry; 2006; 40(11-12):963-71. PubMed ID: 17054564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.